Lyprinol reduces inflammation and improves lung function in a mouse model of allergic airways disease.
BACKGROUND
Asthma is an inflammatory airway disease that is characterized by an influx of eosinophils to the lungs, mucus hypersecretion and T helper type 2 cytokine production. Recent dietary changes, including a decreased ω-3 polyunsaturated fatty acid (PUFA) intake, may have contributed to increased asthma rates and dietary supplementation with marine oil could have clinical benefits.


OBJECTIVE
To assess the effects of dietary supplementation with ω-3 PUFAs on allergic inflammation and lung function using a mouse model of ovalbumin (OVA)-induced allergic airway disease (AAD).


METHODS
BALB/c mice received a daily supplement of either fish oil (rich in ω-3 PUFA) or lyprinol (a complex mixture of various marine lipids plus vitamin E and olive oil) before and during AAD. The effects of supplementation on AAD were assessed.


RESULTS
Lyprinol but not fish oil treatment reduced eosinophil influx into the bronchoalveolar lavage fluid, the lung tissue surrounding the airways and the blood, decreased mucus hypersecretion in the lung and reduced airway hyperresponsiveness (AHR). The effects of lyprinol were not associated with changes in serum IgG1 or IgG2a, or the release of IL-4, IL-5, IL-13 and IFN-γ.


CONCLUSIONS
Lyprinol suppresses the development of allergic inflammation and AHR in AAD. The therapeutic potential of dietary supplementation with lyprinol for asthma warrants further investigation.
Wood
L G
LG
Centre for Asthma and Respiratory Diseases and Hunter Medical Research Institute, The University of Newcastle, Newcastle, NSW, Australia.
Hazlewood
L C
LC
Foster
P S
PS
Hansbro
P M
PM
D000818:Animals; D001249:Asthma / Q000276:immunology / Q000503:physiopathology; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology / Q000276:immunology; D019587:Dietary Supplements; D004195:Disease Models, Animal; D004804:Eosinophils / Q000187:drug effects / Q000276:immunology; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage*; D005395:Fish Oils / Q000008:administration & dosage; D007249:Inflammation / Q000276:immunology / Q000503:physiopathology; D008055:Lipids / Q000008:administration & dosage*; D008168:Lung / Q000187:drug effects / Q000503:physiopathology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D010047:Ovalbumin / Q000276:immunology; D012130:Respiratory Hypersensitivity / Q000276:immunology / Q000503:physiopathology*; D018418:Th2 Cells / Q000187:drug effects / Q000276:immunology
D015525:Fatty Acids, Omega-3; D005395:Fish Oils; D008055:Lipids; C418997:lyprinol; D010047:Ovalbumin